The India Expo Mart in Delhi will host CPhI and P-MEC India with expected attendance of 50,000.
CPhI & P-MEC India, scheduled for Dec. 10-14, 2018, will relocate to the India Expo Mart in Delhi to accommodate increased attendance; more than 50,000 people from 122 countries and almost 1500 exhibitors are expected to attend. The event, organized by UBM, will be hosted in a single venue that is closer to the Indian regulatory and legislative capital than previous shows, the organizers reported in a June 11, 2018 press statement.
“The shift to the Delhi-NCR region, in close geographical proximity to the policy makers, consulates, and government bodies will enhance our community building efforts, as well as the creation of a robust pharma ecosystem,” Yogesh Mudras, managing director, UBM India, commented in the statement.
The organizers also cited increased international interest in the event as a factor in the move, with the numbers of both international and domestic exhibitors requiring a larger, single-site venue. The venue change is also seen by the organizers as a boost to domestically focused markets by bringing a wider remit of attendees and greater access to national regulatory pathways.
UBM noted in the statement that government investment plans-including a $640-million venture capital fund to boost drug discovery and strengthen pharmaceutical infrastructure-and the Pharma Vision 2020 initiative are creating new benefits for government engagement with industry.
The 2018 event will feature the third India Pharma Week with 10 events and activities spanning the Indian Capital, including the Pharma Leader’s Golf Pre-Connect Congress, plant visits, Women in Pharma, Power Breakfast, India Pharma Awards, networking evening, and a closed-door CEO roundtable.
CPhI, P-MEC, and Pharmaceutical Technology are UBM brands.
Source: CPhI India
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.